Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-26T05:49:09.649Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacodynamics of Antiretroviral Chemotherapy

Published online by Cambridge University Press:  21 June 2016

George L. Drusano
George L. Drusano*
Affiliation:
Division of Clinical Pharmacology, Albany Medical College, Albany, New York
*
Division of Clinical Pharmacology Professor of Medicine, Albany Medical College, Albany, NY 12208
Get access Rights & Permissions [Opens in a new window]

Extract

Most clinicians are both familiar and comfortable with antibacterial chemotherapy. In large part, this is due to the relatively broad therapeutic-toxic window presented by most antibacterial agents, especially the beta-lactam class of drugs. Except for the occasional patient, little thought is given to overdosage, even (inappropriately) when organ function is impaired. Rather, the focus has been on providing demonstrably effective concentrations of drug as early in the course of the infection as possible. This has the rational aim of maximizing therapy from the very beginning, in order to minimize mortality and infectious morbidity. This is possible because of the paucity of drug-related morbidity in this setting.

Antiretroviral therapy sometimes has been compared with oncologic chemotherapy, mostly because of the more toxic nature of antiviral agents. This is a mistake. The aim of oncologic chemotherapy is to reduce the number of malignant cells in the body to as close to zero as possible. This is best accomplished by the largest tolerable dose of oncolytic agent. These two linked ideas have driven virtually all of oncologic drug development. Indeed, the explicit aim of Phase 1 and Phase 2 trials in oncolytics is to identify the largest tolerable dose of drug. In contrast to anti-infective chemotherapy, the focus is almost exclusively on the relationship between drug exposure and the development of toxicities.

Type
Clinical Pharmacology of Antibiotics
Information
Infection Control & Hospital Epidemiology , Volume 14 , Issue 9 , September 1993 , pp. 530 - 536
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Bagasra, O, Lischner, HW. Activity of dextran sulfate and other polyanionic polysaccharides against human immunodeticiency virus. J Infect Dis 1988;158:1084–1087.CrossRefGoogle Scholar
2. Lorentsen, KJ, Hendrix, CW, Collins, JM, et al. Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med 1989;111:561–566.CrossRefGoogle ScholarPubMed
3. Cooley, TP, Kunches, LM, Saunders, CA, et al. Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a phase 1 trial. N Engl J Med 1990;322:1340–1345.CrossRefGoogle ScholarPubMed
4. Lambert, JS, Seidlin, M, Reichman, RC, et al. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase 1 trial. N Engl J Med 1990;322:1333–1340.CrossRefGoogle ScholarPubMed
5. Drusano, GL, Yuen, GJ, Morse, G, et al. Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosine in phase 1 trials. Antimicrob Agents Chemother 1992;36:1280–1283.CrossRefGoogle Scholar
6. Drusano, GL, Balis, F, Gitterman, SR, Pizza, l? Pharmacodynamic response to HIV-infected pediatric patients to intravenously administered zidovudine (AZT). Presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 21-24, 1990; Atlanta, Georgia.Google Scholar
7. Drusano, GL, Yuen, GJ, Lambert, JS, Seidlin, M, Dolin, R, Valentine, FT. Relationship between dideoxyinosine exposure, CD, counts, and p24 antigen levels in human immunodeticiency virus infection. A phase 1 trial. Ann Intern Med 1992;116:562–566.CrossRefGoogle Scholar
8. Dudley, MN, Horton, C, Kaul, S, Squires, K, Weitberg, A. Effect of dose and schedule on CD, cell increase with stavudine (D4T): an integrated pharmacokinetic and pharmacodynamic analysis. 8th International Conference on AIDS; July 19-24, 1992; Amsterdam, The Netherlands. Abstract POB3016.Google Scholar
9. Fischl, MA, Boota, AM, Spector, SA, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase 1 and 2 study. Ann Intern Med 1992;116:13–20.Google Scholar
10. Gitterman, SR, Drusano, GL, Balis, F, Pizzo, I? The relationship between serum zidovudine (AZT) levels and granulocyte count in pediatric patients receiving continuous AZT infusion. Presented at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 1989; Houston, Texas.Google Scholar
11. Collier, AC, Bozzette, S, Coombs, RW, et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990;323:1015–1021.CrossRefGoogle ScholarPubMed
12. Fischl, MA, Parker, CB, Pettinelli, C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990;323:1009–1014.CrossRefGoogle ScholarPubMed
13. Gitterman, SR, Drusano, GL. Egorin, MJ, Standiford, HC, the VA Cooperative Study Group. Population pharmacokinetics of zidovudine. Clin Pharmacol Ther 1990;48:161–167.CrossRefGoogle ScholarPubMed
14. Klecker, RW Jr Collins, JM, Yarchoan, R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′.deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987;41:407–412.CrossRefGoogle ScholarPubMed
15. Drusano, GL, Light, P, Josselson, J, et al. Phase 1 dose escalation trial of zidovudine (AZT) in HIV-patients on hemo (HD) and peritoneal (PD) dialysis. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 29-October 2, 1991; Chicago, Illinois. Abstract 762.Google Scholar
16. Stagg, MP, Cretton, EM, Kidd, L, Diasio, RB, Sommadossi, JP. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3'-deoxythymidine. Clin Pharmacol Ther 1992;51:668–676.CrossRefGoogle ScholarPubMed
17. Yarchoan, R, Pluda, JM, Thomas, RV, et al. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990;336:526–529.CrossRefGoogle ScholarPubMed
18. Kahn, JO, Lagakos, SW, Richman, DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581–587.CrossRefGoogle ScholarPubMed